



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Carboplatin

Aug 6, 2014

### Non-proprietary Name

Carboplatin

### Safety measure

Precautions should be revised in the package inserts.

In Clinically significant adverse reactions subsection of Adverse Reactions section, the following texts should be added:

#### Tumour lysis syndrome:

Tumour lysis syndrome may occur. Patients should be carefully monitored by checking serum electrolyte levels and renal function, etc. If any abnormalities are observed, administration of this drug should be discontinued, appropriate measures (e.g. administration of physiological saline solution and/or hyperuricaemia therapeutic agents, and dialysis) should be taken, and patients should be carefully monitored until recovery from such symptoms.

---

#### NOTE

- This drug is designated to prepare a Drug Guide for Patients.